DOTA-LM3 | somatostatin receptor antagonist | SSTR | CAS#1192362-32-5

DOTA-LM3
new

featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125671

CAS#: 1192362-32-5

Description: DOTA-LM3 is a somatostatin receptor ( SSTR ) antagonist.

Chemical Structure

DOTA-LM3

CAS# 1192362-32-5

Instruction

Theoretical Analysis

MedKoo Cat#: 125671
Name: DOTA-LM3
CAS#: 1192362-32-5
Chemical Formula: C69H93ClN16O19S2
Exact Mass: 1,548.59
Molecular Weight: 1,550.170
Elemental Analysis: C, 53.46; H, 6.05; Cl, 2.29; N, 14.46; O, 19.61; S, 4.14

Price and Availability

Size	Price	Availability
10mg	USD 1250	2 Weeks
50mg	USD 2050	2 Weeks
100mg	USD 3850	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: DOTA-LM3; HY-P5126; CS-0774636; DOTALM3; DOTA LM3

IUPAC/Chemical Name: 2,2',2''-(10-(2-((1-((4-((1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamoyl)-10-(4-aminobutyl)-16-(4-hydroxybenzyl)-7-(1-hydroxyethyl)-6,9,12,15,18-pentaoxo-13-(4-ureidobenzyl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl)amino)-3-(4-chlorophenyl)-1-oxopropan-2-yl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid

InChi Key: KOZHSMBONUANKJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C69H93ClN16O19S2/c1-40(87)60-68(104)81-55(66(102)77-50(61(72)97)30-43-9-17-47(88)18-10-43)39-107-106-38-54(67(103)79-53(33-44-11-19-48(89)20-12-44)65(101)78-52(32-42-7-15-46(16-8-42)74-69(73)105)64(100)76-49(62(98)82-60)4-2-3-21-71)80-63(99)51(31-41-5-13-45(70)14-6-41)75-56(90)34-83-22-24-84(35-57(91)92)26-28-86(37-59(95)96)29-27-85(25-23-83)36-58(93)94/h5-20,40,49-55,60,87-89H,2-4,21-39,71H2,1H3,(H2,72,97)(H,75,90)(H,76,100)(H,77,102)(H,78,101)(H,79,103)(H,80,99)(H,81,104)(H,82,98)(H,91,92)(H,93,94)(H,95,96)(H3,73,74,105)

SMILES Code: CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CC=C(C=C2)NC(=O)N)CC3=CC=C(C=C3)O)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)CN5CCN(CCN(CCN(CC5)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(CC6=CC=C(C=C6)O)C(=O)N)O

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,550.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Zhu W, Jia R, Yang Q, Cheng Y, Zhao H, Bai C, Xu J, Yao S, Huo L. A
prospective randomized, double-blind study to evaluate the diagnostic efficacy
of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in patients with
well-differentiated neuroendocrine tumors: compared with ⁶⁸Ga-
DOTATATE. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1613-1622. doi:
10.1007/s00259-021-05512-y. Epub 2021 Dec 7. PMID: 34874478.

2: Zhu W, Cheng Y, Jia R, Zhao H, Bai C, Xu J, Yao S, Huo L. A Prospective,
Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and
Dosimetry of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in Patients
with Well-Differentiated Neuroendocrine Tumors. J Nucl Med. 2021
Oct;62(10):1398-1405. doi: 10.2967/jnumed.120.253096. Epub 2021 Feb 12. PMID:
33579804; PMCID: PMC8724897.

3: Severin GW, Kristensen LK, Nielsen CH, Fonslet J, Jensen AI, Frellsen AF,
Jensen KM, Elema DR, Maecke H, Kjær A, Johnston K, Köster U. Neodymium-140 DOTA-
LM3: Evaluation of an In Vivo Generator for PET with a Non-Internalizing
Vector. Front Med (Lausanne). 2017 Jul 12;4:98. doi: 10.3389/fmed.2017.00098.
PMID: 28748183; PMCID: PMC5506079.

4: Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, Köster
U, Schibli R, van der Meulen NP, Müller C. Combination of terbium-161 with
somatostatin receptor antagonists-a potential paradigm shift for the treatment
of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022
Mar;49(4):1113-1126. doi: 10.1007/s00259-021-05564-0. Epub 2021 Oct 8. PMID:
34625828; PMCID: PMC8921065.

5: Borgna F, Barritt P, Grundler PV, Talip Z, Cohrs S, Zeevaart JR, Köster U,
Schibli R, van der Meulen NP, Müller C. Simultaneous Visualization of
¹⁶¹Tb- and ¹⁷⁷Lu-Labeled Somatostatin Analogues Using
Dual-Isotope SPECT Imaging. Pharmaceutics. 2021 Apr 12;13(4):536. doi:
10.3390/pharmaceutics13040536. PMID: 33921467; PMCID: PMC8070648.

Your view history

DOTA-LM3 new featured